← Back

Wire · opportunities

IQVIA Partners With Medera on Cardiac Gene Therapy Development

Published

5 August 2026

Topic

opportunities

Sectors

Biotech

Geography

United States

Source

Read at clinicaltrialvanguard.com

Verified

Fusion42 · 31 August 2026 · Fusion42 review

IQVIA partners with Medera to accelerate execution of cardiac gene therapy clinical trials in the US, leveraging IQVIA's recruitment, regulatory, and data infrastructure to overcome operational bottlenecks in challenging cardiac gene therapy development.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ The Wire takeaway

You can use IQVIA's expanded clinical trial infrastructure as a lever to speed your cardiac gene therapy trial enrolment and regulatory filings. The FDA Modernization Act's shift to human tissue platforms opens regulatory doors you should move quickly to explore before competition increases.

Coverage

3 sources · 5 Aug 2026

Related on Wire

Topics

Biotechcardiac-gene-therapyclinical-trialsregulatory-supportFDA-designationsclinical-operations